Expression OF p53, p21WAF1/CIP1 , p16INK4A and Ki-67 proteins in serous ovarian tumors

• Main Authors: Buchynska, L.G., Nesina, I.P., Yurchenko, N.P., Bilyk, O.O., Grinkevych, V.N., Svintitsky, V.S.
• Format: Article
• Language: English
• Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2007
• Series: Experimental Oncology
• Subjects: Original contributions
• Online Access: http://dspace.nbuv.gov.ua/handle/123456789/138561

Aim: The analysis of p53, p21WAF1/CIP1, p16INK4a and Ki-67 expression in serous ovarian carcinomas of different grade. Materials and Methods: In total, 43 ovarian adenocarcinomas and 8 non-altered ovarian epithelial tissues were immunohistochemically investigated for expression of Кі-67, р53, р21WAF1/CIP1 and р16INK4a. Results: It has been shown that expression of Кі-67, р53, р21WAF1/CIP1 and р16INK4a in non-altered ovarian epithelial tissue is absent. Serous ovarian carcinomas are characterized by high proliferative activity (PI Кі-67 = 30.0 ± 0.3%), р53 and р16INK4a overexpression (LI is 40.3 ± 0.3% and 31.1 ± 0.6% respectively) and low expression of р21WAF1/CIP1 (LI = 6.8 ± 0.3%). The association between expression of these markers and ovarian tumor grade was defined: the maximal level of Кі-67, р53 and p16/INK4a and minimal of p21WAF1/CIP1 expression were observed in G3 tumors. So, low p21WAF1/CIP1 expression (LI < 7.0%) combined with р16INK4a overexpression is considered to be the factor for a poor prognosis in serous ovarian cancer. Conclusions: The present study has indicated that biomolecular markers of cell proliferation along with traditional clinical and morphologic characteristics can be used for differential diagnostics of ovarian tumors.